Stay updated with breaking news from Ranibizumab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biopharmaceutical company Outlook Therapeutics, Inc. (OTLK) announced Monday the receipt of the official minutes from the Type A meeting with the U.S. Food and Drug Administration (FDA) held in October 2023. ....
Lupin has inked a licensing pact for the commercialisation and marketing of Ranibizumab, a biosimilar of Lucentis, in various countries including Saudi Arabia, UAE, Iraq and Lebanon. ....
The ranibizumab biosimilar was the first in ophthalmology to the US market in 2022, but its competition has already had a year of interchangeability exclusivity. ....